| 24.1608 0.391 (1.64%) | 04-28 11:20 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.42 | 1-year : | 37.87 |
| Resists | First : | 27.76 | Second : | 32.42 |
| Pivot price | 22.68  |
|||
| Supports | First : | 20.8 | Second : | 16.5 |
| MAs | MA(5) : | 24.43  |
MA(20) : | 21.63 |
| MA(100) : | 20.98 |
MA(250) : | 18.26 |
|
| MACD | MACD : | 1.4 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 61.1 |
D(3) : | 64.9 |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 30 | Low : | 3.42 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ URGN ] has closed below upper band by 34.4%. Bollinger Bands are 66.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 25.05 - 25.2 | 25.2 - 25.32 |
| Low: | 23.28 - 23.48 | 23.48 - 23.62 |
| Close: | 23.52 - 23.8 | 23.8 - 24.01 |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Mon, 27 Apr 2026
BlackRock (URGN) discloses 2.52M shares, 5.2% stake reported - Stock Titan
Thu, 23 Apr 2026
URGN Stock Price, Quote & Chart | UROGEN PHARMA LTD (NASDAQ:URGN) - ChartMill
Mon, 20 Apr 2026
Piper Sandler Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Sun, 12 Apr 2026
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substant - GuruFocus
Sun, 12 Apr 2026
UroGen Pharma (URGN) Is Up 14.6% After Phase 3 ENVISION Data And LG-UTUC Outreach Push - Sahm
Thu, 05 Mar 2026
UroGen Pharma Ltd. (URGN) Stock Analysis: A Biotech Gem With 76.71% Potential Upside - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 99.3 (%) |
| Shares Short | 8,350 (K) |
| Shares Short P.Month | 8,020 (K) |
| EPS | -3.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.19 |
| Profit Margin | -139.9 % |
| Operating Margin | -50.6 % |
| Return on Assets (ttm) | -32.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 54 % |
| Gross Profit (p.s.) | 1.99 |
| Sales Per Share | 2.25 |
| EBITDA (p.s.) | -2.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -162 (M) |
| Levered Free Cash Flow | -99 (M) |
| PE Ratio | -7.5 |
| PEG Ratio | 0 |
| Price to Book value | -10.98 |
| Price to Sales | 10.6 |
| Price to Cash Flow | -7.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|